炎症性肠病的药物治疗现状

卞莹莹; 王洁; 李安; 开国银; 陆一鸣

doi:10.3969/j.issn.1006-0111.2017.03.002

炎症性肠病的药物治疗现状

doi: 10.3969/j.issn.1006-0111.2017.03.002

1.
上海师范大学生命与环境科学学院, 上海 200234
2.
第二军医大学药学院生化药学教研室, 上海 200433

基金项目: 国家自然科学基金资助项目（30500093，81274162）；国家科技部"重大新药创制"专项（2009ZX09103-690）；上海市科委生物医药领域科技支撑项目（16431904400）；上海市教委科研创新项目（14ZZ077）

The research status of the drug therapy for inflammatory bowel disease

1.
College of Life and Environment Science, Shanghai Normal University, Shanghai 200234, China
2.
Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

摘要: 炎症性肠病（inflammatory bowel disease，IBD）目前是消化系统疾病的研究热点之一，主要包括溃疡性结肠炎（ulcerative colitis，UC）和克罗恩病（Crohn's disease，CD），其发病机制尚未完全阐明，也尚无针对IBD的有效治疗药物。随着对IBD发病机制的深入研究，出现了一些新型药物和制剂。笔者就IBD及其药物治疗的研究现状作一简要综述。
- 炎症性肠病 /
- 溃疡性结肠炎 /
- 克罗恩病 /
- 药物治疗
Abstract: Research on the inflammatory bowel disease(IBD) is a hot topic in the field of digestive system disease. IBD mainly consists of ulcerative colitis(UC) and Crohn's disease(CD). The pathogenesis of IBD has not been fully understood. So far, there is no specific medication for IBD. A number of novel medicines and preparations have emerged with the research progress on the pathogenesis of IBD. The research status on IBD drug therapy is briefly reviewed in this paper.
- inflammatory bowel disease /
- ulcerative colitis /
- Crohn's disease /
- drug therapy

[1]	Bernstein CN, Fried M, Krabshuis JH, et al. 2010年世界胃肠病学组织关于炎症性肠病诊断和治疗的实践指南[J]. 胃肠病学,2010,15(9):548-558.
[2]	郭小芹. IL-17/IL-17R通路在炎症性肠病中的免疫调节机制研究[D].北京:中国人民解放军军事医学科学院,2013.
[3]	Rammeart DC, Canling SR. Inflammatory bowel disease: cause and immunobiology[J]. Lancet,2007,369(9673):1627-1640.
[4]	Parkes M. The genetics universe of Crohn's disease and ulcerative colitis[J]. Dig Dis,2012,30(Suppl 1):78-81.
[5]	Ye BD, Yang SK, Cho YK, et al. Clinical features and long-term prognosis of Crohn's disease in Korea[J]. Scand J Gastroenterol,2010,45(10):1178-1185.
[6]	牛润章,张兰兰,司依馨. 炎症性肠病的病因及诊治研究进展[J]. 实用医药杂志,2014,31(5):461-463.
[7]	欧阳钦. 炎症性肠病的病因和发病机制[J]. 实用医学杂志,2003,19(5):448-449.
[8]	Maesla S, Hsu LC, Lin H, et al. Nod-mutation in Crohn's disease potenliales NF-kappaB activity and IL-beta processing[J]. Science,2005,307(5710):734-738.
[9]	肖梅,吴正祥. 炎症性肠病的病因研究进展[J]. 安徽医药,2005,9(12):886-889.
[10]	Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeatic alternative[J]. Gastroenterology,1999,116(5):1246-1249.
[11]	欧阳钦. 炎症性肠病发病机制与治疗研究进展[J]. 中国处方药,2004,23(4):15-19.
[12]	Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induced and perpetuate experimental colitis in rats and mice[J]. Infect Immune,2001,69(4):2277-2285.
[13]	郭璟. 4-氨基水杨酸抗炎性肠病衍生物的合成研究[D]. 山西:山西医科大学,2004.
[14]	黄雪彪. 炎症性肠病的药物治疗[J]. 临床药物治疗杂志,2003,1(4):27-32.
[15]	Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance of Crohn's disease: a meta-analysis adjusted for confounding variables[J]. Gastroenterology,1997,113(5):1465-1473.
[16]	Campieri M, Lanfranchi GA, Bertoni F, et al. A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis[J].Digestion,1984,29(4):204-208.
[17]	靳宝芬. 4-氨基水杨酸和5-氨基水杨酸抗炎作用及作用机制研究[D].山西:山西医科大学,2014.
[18]	蒋蔚茹. 炎症性肠病的认识与治疗进展[J]. 上海医药,2010,31(5):207-210.
[19]	刘凡. 炎症性肠病药物治疗现状与进展[J]. 沈阳医学院学报,2006,8(4):241-242.
[20]	Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2006,24(2):331-342.
[21]	Gao X, Zhang FB, Ding L, et al. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine in inflammatory bowel disease patients[J]. Eur J Gastroenterol Hepatol,2012,24(8):958-964.
[22]	Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma[J]. Gastroenterol,2000,118(6):1018.
[23]	Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopu-rine, mesalamine, or placebo: a 2-year trial[J]. Gastroenterology, 2004,127(3):723-729.
[24]	Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease[J]. Gastroenterology,2006,130(3):935-939.
[25]	Feagan G, John M. Low-Dose Cyclosporine for the Treatment of Crohn's Disease[J]. Med, 1994,330(26):1846-1851.
[26]	Cheifetz AS, Stern J, Garud S, et al. Cyclosporine is safe and effective in patients with severe ulcerative colitis[J]. Clin Gastroenterol,2011,45(2):107-112.
[27]	崔静. 炎症性肠病发病机制和治疗方面某些进展[D].郑州:郑州大学,2004.
[28]	王俊珊,刘占举. 炎症性肠病的诊断和药物治疗相关指南解读[J]. 世界临床药物, 2005,36(12):809-813.
[29]	黄瑛,王玉环. 儿童炎症性肠病的药物治疗[J]. 世界临床药物,2009,30(8):459-464.
[30]	李世荣. 生物靶向药物在炎症性肠病中的应用现状[J]. 中国新药杂志,2010,19(19):1750-1757.
[31]	杨志红,邓彤斌,王梦明,等. 炎症性肠病的病因学和药物治疗研究进展[J]. 中国药师, 2013,16(6): 905-907.
[32]	高树娟,施瑞华. 炎症性肠病治疗的新进展[J]. 世界华人消化杂志,2012,36:3742-3747.
[33]	Papadakis KA. Safety and efficacy of ada limumab in Crohn's disease patients with an attenuated response to infliximab[J]. Gastroenterology,2011,100(1):75-79.
[34]	Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease[J]. Aliment Pharmacol Ther,2010,132(1):1296-1309.

[1]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
[2]	夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞. 核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
[3]	丁千雪, 尚圣兰, 余梦辰, 余爱荣. 机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
[4]	戴菲菲, 傅翔, 陈琼年, 俞苏纯. 上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
[5]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[6]	陈怡君, 王卓, 何苗, 张宇, 田泾. 泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
[7]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[8]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
[9]	张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫. 基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
[10]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[11]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[12]	徐飞, 陈瑾, 鲁育含, 李志勇. 肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
[13]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[14]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[15]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[16]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[17]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[18]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
[19]	宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦. 脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
[20]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049

点击查看大图

计量

文章访问数: 3962
HTML全文浏览量: 612
PDF下载量: 1212
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

炎症性肠病的药物治疗现状

doi: 10.3969/j.issn.1006-0111.2017.03.002

The research status of the drug therapy for inflammatory bowel disease

计量

炎症性肠病的药物治疗现状

doi: 10.3969/j.issn.1006-0111.2017.03.002

1. 上海师范大学生命与环境科学学院, 上海 200234

2. 第二军医大学药学院生化药学教研室, 上海 200433

English Abstract

The research status of the drug therapy for inflammatory bowel disease

1. College of Life and Environment Science, Shanghai Normal University, Shanghai 200234, China

2. Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

全文HTML

目录

留言板

炎症性肠病的药物治疗现状

doi: 10.3969/j.issn.1006-0111.2017.03.002

The research status of the drug therapy for inflammatory bowel disease

计量

出版历程

炎症性肠病的药物治疗现状

doi: 10.3969/j.issn.1006-0111.2017.03.002

1. 上海师范大学生命与环境科学学院, 上海 200234 2. 第二军医大学药学院生化药学教研室, 上海 200433

English Abstract

The research status of the drug therapy for inflammatory bowel disease

1. College of Life and Environment Science, Shanghai Normal University, Shanghai 200234, China 2. Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

全文HTML

目录

1. 上海师范大学生命与环境科学学院, 上海 200234

2. 第二军医大学药学院生化药学教研室, 上海 200433

1. College of Life and Environment Science, Shanghai Normal University, Shanghai 200234, China

2. Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China